Default company panoramic image
Logo

Third Eye Diagnostics, Inc.

Developing medical devices for non-invasive diagnosis and management of traumatic brain injury and elevated intracranial pressure (ICP).

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded October 2010
  • Employees 5
  • Website 3-e-d.com

Company Summary

3ED is developing the CerePress™, a handheld medical triage device that addresses the unmet need for noninvasive diagnosis of elevated ICP. The rapid detection of elevated ICP in brain injuries is critical for physicians and first responders to assess the degree of injury & develop the best therapy to reduce the chance of death & disability. Early detection of elevated ICP will lead to better patient outcomes and reduced healthcare costs.

Team

  • Default avatar
    Terry A Fuller
    President and CEO

    Terry A. Fuller, Ph.D. has over 25 years of entrepreneurial business management, technology development, marketing and sales experience with emerging and high-growth start-up and early-stage medical device and pharmaceutical companies. He has held positions of CEO, COO, and EVP Technology for both publicly traded and private corporations (IOLab, a J&J Co., Surgical Laser Technologies, Inc., Wellcore, Inc., Laser SkinToner, Inc., SubLase, Inc.)

  • Default avatar
    Anthony J Bellezza
    COO

    Anthony Bellezza, Ph.D. has direct experience in the formation and operation of startup companies. Prior to Third Eye Diagnostics, he was a Senior Engineer in the Biomechanics Practice at Exponent, Inc., and assisted companies ranging from startups to Fortune 500 in new product development. Scientifically, he has spent much of his career studying the mechanical properties of the eye, especially in response to changes in intraocular pressure.

  • Default avatar
    William Lai
    VP of Biomedical Engineering

    William Lai, Ph.D. has experience with a variety of diagnostic medical devices from intellectual property, regulatory compliance, and product development perspectives. Dr. Lai has conducted research in the biocompatibility of biomaterials used in dental and orthopedic applications at the University of Pennsylvania. He has 5 years experience in the research and development operations of an early stage medical technology development company.

Advisors

  • Default avatar
    General Counsel: Blank Rome, LLP; IP: Woodcock Washburn, LLP
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    Ben Franklin Technology Partners Northeast
    Unconfirmed
    Default avatar
    National Science Foundation
    Unconfirmed
    Default avatar
    Angel Investor
    Unconfirmed